Aroa Biosurgery (ASX:ARX) EBIT per Share : A$-0.03 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery EBIT per Share?

Aroa Biosurgery's EBIT per Share for the six months ended in Mar. 2024 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was A$-0.03.

During the past 3 years, the average EBIT per Share Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Aroa Biosurgery's EBIT per Share or its related term are showing as below:

ASX:ARX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 2.1 Med: 2.1 Max: 2.1
Current: 2.1

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Aroa Biosurgery was 2.10% per year. The lowest was 2.10% per year. And the median was 2.10% per year.

ASX:ARX's 3-Year EBIT Growth Rate is ranked worse than
54.7% of 724 companies
in the Medical Devices & Instruments industry
Industry Median: 5.75 vs ASX:ARX: 2.10

Aroa Biosurgery's EBIT for the six months ended in Mar. 2024 was A$-4.65 Mil.

Aroa Biosurgery EBIT per Share Historical Data

The historical data trend for Aroa Biosurgery's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery EBIT per Share Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT per Share

-0.05

-0.02

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EBIT per Share	Get a 7-Day Free Trial			-0.01	0.01	-0.01	-0.01	-0.01

Aroa Biosurgery EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Aroa Biosurgery's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.402	/	343.825
=	-0.02

Aroa Biosurgery's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.654	/	344.375
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03

Aroa Biosurgery (ASX:ARX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Aroa Biosurgery EBIT per Share Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines